RHYTHM PHARMACEUTICALS, INC. Earnings Per Share, Basic and Diluted
RHYTHM PHARMACEUTICALS, INC. (RYTM) reported Earnings Per Share, Basic and Diluted of -$0.70 per share for the 3-month period ending 2021-09-30, per its 10-Q filed 2021-11-02.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2021-11-02
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.70.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2020-09-30 was -$0.77.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2020-06-30 was -$0.71.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for the quarter ending 2020-03-31 was -$0.78.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2020 was -$3.04.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2019 was -$3.86.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2018 was -$2.39.
- RHYTHM PHARMACEUTICALS, INC. earnings per share, basic and diluted for fiscal 2017 was -$2.83.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2021-09-30 | -$0.70 10-Q · filed 2021-11-02 | -$0.54 10-Q · filed 2021-11-02 | ||
| 2020-12-31 | -$3.04 10-K · filed 2021-03-01 | |||
| 2020-09-30 | -$0.77 10-Q · filed 2021-11-02 | -$2.25 10-Q · filed 2021-11-02 | ||
| 2020-06-30 | -$0.71 10-Q · filed 2020-08-03 | -$1.48 10-Q · filed 2020-08-03 | ||
| 2020-03-31 | -$0.78 10-Q · filed 2020-05-04 | |||
| 2019-12-31 | -$0.78 10-K · filed 2020-03-02 | -$1.80 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$3.01 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$3.86 10-K · filed 2021-03-01 |
| 2019-09-30 | -$1.04 10-Q · filed 2020-11-02 | -$2.28 derived: net income ÷ weighted average shares · filed 2020-11-02 | -$3.13 10-Q · filed 2020-11-02 | -$3.87 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2019-06-30 | -$1.24 10-Q · filed 2020-08-03 | -$2.08 10-Q · filed 2020-08-03 | -$2.82 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$3.34 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2019-03-31 | -$0.84 10-Q · filed 2020-05-04 | -$1.58 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.10 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.64 derived: net income ÷ weighted average shares · filed 2021-03-01 |
| 2018-12-31 | -$0.74 10-K · filed 2020-03-02 | -$1.26 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.79 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.39 10-K · filed 2021-03-01 |
| 2018-09-30 | -$0.52 10-K · filed 2020-03-02 | -$1.03 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.63 10-Q · filed 2019-11-01 | -$2.04 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2018-06-30 | -$0.52 10-K · filed 2020-03-02 | -$1.12 10-Q · filed 2019-07-29 | -$1.53 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$2.41 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2018-03-31 | -$0.60 10-K · filed 2020-03-02 | -$1.01 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$1.93 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$2.65 derived: net income ÷ weighted average shares · filed 2020-03-02 |
| 2017-12-31 | -$0.41 10-K · filed 2019-03-08 | -$1.35 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$2.10 derived: net income ÷ weighted average shares · filed 2020-03-02 | -$2.83 10-K · filed 2020-03-02 |
| 2017-09-30 | -$1.78 10-K · filed 2019-03-08 | -$2.34 derived: net income ÷ weighted average shares · filed 2019-03-08 | -$3.02 10-Q · filed 2018-11-09 | -$3.91 derived: net income ÷ weighted average shares · filed 2019-03-08 |
| 2017-06-30 | -$0.78 10-K · filed 2019-03-08 | -$1.52 10-Q · filed 2018-08-08 | -$2.42 derived: net income ÷ weighted average shares · filed 2019-03-08 | -$3.13 derived: net income ÷ weighted average shares · filed 2019-03-08 |
| 2017-03-31 | -$0.74 10-K · filed 2019-03-08 | -$1.64 derived: net income ÷ weighted average shares · filed 2019-03-08 | -$2.34 derived: net income ÷ weighted average shares · filed 2019-03-08 | |
| 2016-12-31 | -$0.90 8-K · filed 2018-11-09 | -$1.60 derived: net income ÷ weighted average shares · filed 2019-03-08 | -$2.85 10-K · filed 2019-03-08 | |
| 2016-09-30 | -$0.71 8-K · filed 2018-11-09 | -$1.95 10-Q · filed 2017-11-14 | ||
| 2016-06-30 | -$0.64 8-K · filed 2018-11-09 | |||
| 2016-03-31 | -$0.61 8-K · filed 2018-11-09 | |||
| 2015-12-31 | -$1.18 8-K · filed 2018-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |